Education
About Us
Working with TipRanks
Follow Us
Repligen (RGEN)
NASDAQ:RGEN
Top Page
Repligen
(NASDAQ:RGEN)
Select Model
Select Model
Rating:60Neutral
Price Target:
$141.00
▲(9.53% Upside)
Action:ReiteratedDate:02/25/26
The score is driven by improving fundamentals and a constructive earnings outlook with guided growth and margin expansion. These positives are held back by clearly bearish technicals and an extremely high P/E with no dividend support.
Positive Factors
Cross-selling & commercial funnel
A deeper commercial funnel and 2.5x cross-sell penetration indicate durable wallet-share gains with existing biopharma customers. Higher attach rates to installed bases drive recurring consumable revenue, improve lifetime customer economics, and reduce new-account acquisition costs, supporting steady revenue and margin resilience over multiple quarters.
Strong cash generation & solid liquidity
Large cash reserves and positive operating/free cash flow provide structural financial flexibility to fund R&D, M&A, capex (~3%–4% of revenue), and margin investments without stressing the balance sheet. This liquidity supports strategic initiatives and cushions near-term cyclical softness in bioprocessing demand.
Product innovation and strategic M&A
Targeted acquisitions and partnerships broaden the product set and add technical capabilities (ML in filtration), accelerating access to adjacent markets. Coupled with recent launches, this builds a more differentiated, higher-margin portfolio and strengthens long-term competitive positioning versus point-solution vendors.
Negative Factors
Profitability below prior peak
Although profitability recovered in 2025, margins remain structurally below prior cycle peaks, limiting returns on a large equity base. Sustained margin improvement is required to convert strong cash balances into attractive ROE; failure to do so could keep capital returns and reinvestment capacity constrained.
Gene therapy demand headwind
A multi-point, modality-specific decline in gene-therapy customer demand is a structural risk for the Filtration franchise, which can depress long-term segment growth rates. Concentration in customer modalities increases sales volatility and may delay recovery in filtration-related consumables and systems demand.
Rising Opex and policy/tariff uncertainty
Sustained higher operating expense from investments (legal, IT, AI, hires) plus tariff and policy surcharges create recurring margin pressure. If incremental costs persist or policy uncertainty delays customer CapEx, margin expansion targets and cash conversion could be harder to achieve over several quarters.
Repligen (RGEN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.25B
Dividend YieldN/A
Average Volume (3M)754.77K
Price to Earnings (P/E)148.9
Beta (1Y)0.95
Revenue Growth11.74%
EPS GrowthN/A
CountryUS
Employees1,778
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.49
Shares Outstanding56,331,110
10 Day Avg. Volume866,724
30 Day Avg. Volume754,771
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.38
Price to Sales (P/S)12.48
P/FCF Ratio98.13
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue9.99
Enterprise Value/Gross Profit19.62
Enterprise Value/Ebitda41.75
Forecast
1Y Price Target
$188.00Price Target Upside46.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)2.08
Revenue Forecast (FY)$822.45M
Repligen Business Overview & Revenue Model
Company DescriptionRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
How the Company Makes MoneyRepligen generates revenue through the sale of its bioprocessing products and solutions to pharmaceutical and biotechnology companies. The company's revenue model is primarily based on product sales, which include consumables, instruments, and systems used in the biomanufacturing process. Key revenue streams come from the sale of chromatography resins, filtration systems, and other essential bioprocessing technologies. Additionally, Repligen benefits from long-term partnerships with major pharmaceutical companies, which often involve supply agreements for its proprietary products. The company's focus on innovation and expanding its product portfolio, coupled with increasing demand for biologics, further contributes to its earnings.
Repligen Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 05, 2026
Earnings Call Sentiment Positive
Overall the call was constructive and optimistic: management reported solid revenue acceleration (Q4 and full‑year growth above expectations), meaningful margin expansion, strong cash generation, successful product launches and acquisition integrations, and provided growth and margin guidance for 2026. The company also highlighted several near-term headwinds—muted capital equipment demand, a gene therapy customer-facing headwind, tariff and policy uncertainty, M&A/FX dilution to reported margins, and increased investments in Fit-for-Growth—that temper upside visibility. On balance, the positives (broad-based franchise strength, margin expansion, strong cash and funnel, and prudent but constructive guidance) substantially outweigh the cited risks.Q4-2025 Updates
Positive Updates
Quarter and Full-Year Revenue Growth
Q4 revenue of $198M, up 18% reported and 14% organic year-over-year; full-year 2025 revenue of $738M, up 16% reported and on an organic non-COVID basis.
Strong Franchise Performance
Proteins: >30% growth in Q4 and 31% for the year; Analytics: >30% in Q4 and 37% for the year (21% excluding 908 acquisition); Chromatography: >25% in Q4 and 25% for the year; Filtration: high single‑digit growth in Q4 and 8% for the year (11% non‑COVID). Consumables grew >20% in the quarter.
Margin Expansion and Profitability
Q4 adjusted gross margin 52.4% (+170 bps YoY); full-year gross margin 52.6% (~+220 bps YoY). Adjusted operating margin 13.8% for 2025 (+90 bps YoY reported; +240 bps excluding M&A and FX). Full-year adjusted EBITDA margin 19% (up ~50 bps reported; ~+230 bps excl. M&A/FX).
Cash Generation and Balance Sheet Strength
Cash and marketable securities of $768M at year-end (up $90M sequentially). Full-year cash flow from operations of $117M; Q4 operating cash of $26M; Q4 CapEx $8M.
Product Innovation and Go-to-Market Execution
Multiple product launches in 2025 (SoloVPE PLUS, ProConnex MixOne, three new catalog resins) and traction on SoloVPE PLUS upgrade cycle (installed base 1,500–2,000 units, under 100 upgrades done in late 2025). Sales organization increasingly cross-selling (2.5x product lines to key accounts vs 2019).
M&A and Strategic Partnerships Progress
Acquired 908 Devices' bioprocessing portfolio and progressed Tantti integration; strategic partnership and minority investment in Novasign to integrate ML into filtration systems. Acquisitions contributed ~1 point to reported growth in 2025.
2026 Financial Guidance
Guidance of $810M–$840M revenue (9%–13% organic growth, 10%–14% reported). Gross margin guidance 53.6%–54.1% (≈+125 bps YoY at midpoint). Adjusted operating income guidance $122M–$130M and adjusted EPS $1.93–$2.01 (≈+15% at midpoint). CapEx expected ~3%–4% of revenue.
Commercial Funnel and Strategic Priorities
Company reports highest-ever high-probability sales funnel (>50% probability opportunities), continued focus on cross-selling, Asia Pacific expansion, services growth (services ~6% of sales in 2025 with target to reach ~10% over time) and Fit-for-Growth investments (AI, IT, leadership hires).
Negative Updates
Muted Capital Equipment / Downstream Demand
Capital equipment revenue effectively flat year-over-year (though up 10% vs prior quarter); management described relatively muted equipment demand and tough comps for downstream systems, with downstream/CapEx expected to be broadly flat in 2026 absent macro improvement.
Gene Therapy Customer Headwind
Guidance incorporates a headwind from a gene therapy platform (management cited a 2-point headwind to overall 2026 guidance and a 3-point headwind specifically to Filtration), contributing to cautious first-half pacing.
Tariffs, MFN Policy and FDA Uncertainty
Supreme Court ruling and tariff regime create uncertainty; company assumes several million dollars of tariff surcharges in 2026 (≈50 bps margin headwind). Management flagged potential delays in large pharma CapEx decisions while customers digest MFN and other policy moves, creating downside risk to growth cadence.
M&A and FX Dilution to Near-Term Margins
M&A and foreign exchange diluted reported operating margin (management stated adjusted operating margin excluding M&A/FX expanded ~240 bps, implying M&A/FX reduced reported improvement). M&A-related OpEx and integration costs reduced near-term margin performance (≈$19M of increase related to M&A/FX).
OpEx Step-Up and Investment Spend
Operating expenses increased year-over-year (~$49M increase in OpEx), driven by Fit-for-Growth investments (legal, finance, IT, AI), and merit/comp inflation (~5 percentage points of the increase). OpEx is expected to step up in Q1 2026 due to annual compensation increases and investments.
Market/Modality Headwinds and Regional Variability
mRNA demand cited as a headwind to new modalities; China remains a small percentage of revenue (~2%–3%) despite two quarters of improvement and management notes it is still rebuilding commercial footprint—growth there is expected but from a low base.
Interest Income and Other Income Pressure
Adjusted other income assumed lower in 2026 (management assumes ~$18M) and 2025 saw ~$2M lower interest income vs prior year due to declining interest rates, slightly offsetting operating gains.
Company Guidance
Repligen guided 2026 revenue of $810–840M (10%–14% reported, 9%–13% organic), reflecting roughly a 1‑point FX tailwind and a multi‑point (≈2–3 point) gene‑therapy platform headwind; by franchise the plan assumes Filtration and Chromatography/Proteins grow in the low double‑digits (Filtration bearing the gene‑therapy drag) and Analytics grows >20%. Management expects adjusted gross margin of 53.6%–54.1% (≈+125 bps YoY at the midpoint, with ~50 bps tariff‑surcharge headwind), adjusted income from operations of $122–130M (implying ~150 bps operating‑margin expansion at the midpoint), adjusted other income ≈$18M, an adjusted effective tax rate of 22%–23%, and adjusted diluted EPS of $1.93–$2.01 (+$0.22–$0.30 vs. 2025, ≈+15% at the midpoint). They assume ~48% of revenue in H1 (Q1 down only low single digits sequentially from Q4), modest Q1 gross‑margin expansion, an OpEx step‑up in Q1 with flat‑to‑modestly higher OpEx thereafter, CapEx of ~3%–4% of revenue, and guidance that reflects euro–dollar FX similar to H2 2025 plus several million dollars of tariff surcharges.Repligen Financial Statement Overview
Summary
Fundamentals are improving: 2025 returned to positive net income and maintained positive free cash flow with moderate leverage supported by a large equity base. Offsets are weaker profitability versus 2021–2022, less consistent recent revenue growth after the 2023 decline, and some softening/volatility in cash-flow efficiency.Income Statement
Profitability has recovered in 2025 (annual) with positive net income ($48.9M) after a loss in 2024, but margins remain well below the stronger 2021–2022 period (net margin ~6.6% in 2025 vs ~19–23% in 2021–2022). Revenue growth is positive but modest recently (2025 +4.29%, 2024 ~flat) following a large decline in 2023, indicating a slower and less consistent growth trajectory. Note: 2025 gross profit and margin are shown as 0, which limits margin quality assessment for that year.64
Positive
Balance Sheet
The balance sheet looks solid with a large equity base ($2.11B) supporting moderate leverage (debt-to-equity ~0.33 in 2025), though leverage has risen versus 2020–2022 levels. Returns on equity are currently low (~2.3% in 2025) and were negative in 2024, signaling that profitability hasn’t yet fully caught up with the capital base despite the improved earnings in 2025.72
Positive
Cash Flow
Cash generation is healthy with positive operating cash flow ($117.4M) and free cash flow ($94.0M) in 2025, and cash conversion is decent (free cash flow about 80% of net income). However, free cash flow declined in 2025 (-11.8%) after improvement in 2024, and operating cash flow relative to net income weakened in 2025 versus 2024, suggesting some near-term volatility in cash efficiency.70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 738.26M | 634.44M | 632.36M | 801.54M | 670.53M |
| Gross Profit | 347.62M | 274.64M | 278.44M | 455.71M | 391.25M |
| EBITDA | 164.30M | 80.26M | 145.32M | 277.31M | 203.27M |
| Net Income | 48.89M | -25.51M | 35.60M | 185.96M | 128.29M |
Balance Sheet | |||||
| Total Assets | 2.95B | 2.83B | 2.83B | 2.53B | 2.36B |
| Cash, Cash Equivalents and Short-Term Investments | 767.63M | 757.36M | 751.32M | 623.76M | 603.81M |
| Total Debt | 689.95M | 686.25M | 711.80M | 422.96M | 366.05M |
| Total Liabilities | 843.57M | 856.95M | 866.34M | 620.90M | 608.29M |
| Stockholders Equity | 2.11B | 1.97B | 1.96B | 1.91B | 1.75B |
Cash Flow | |||||
| Free Cash Flow | 93.90M | 142.49M | 74.93M | 38.74M | 47.74M |
| Operating Cash Flow | 117.42M | 175.39M | 113.92M | 172.08M | 119.02M |
| Investing Cash Flow | -298.47M | -86.38M | -123.28M | -233.24M | -221.17M |
| Financing Cash Flow | -15.21M | -82.90M | 248.96M | -13.34M | 961.00K |
Repligen Technical Analysis
Negative
128.73
Price Trends
154.33
Negative
155.06
Negative
139.14
Negative
Market Momentum
-6.73
Positive
28.14
Positive
55.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Negative. The current price of 128.73 is below the 20-day moving average (MA) of 139.24, below the 50-day MA of 154.33, and below the 200-day MA of 139.14, indicating a bearish trend. The MACD of -6.73 indicates Positive momentum. The RSI at 28.14 is Positive, neither overbought nor oversold. The STOCH value of 55.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RGEN.
Repligen Risk Analysis
Repligen disclosed 41 risk factors in its most recent earnings report. Repligen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Repligen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $9.25B | 24.43 | 15.28% | 1.50% | 2.50% | 25.05% | |
68 Neutral | $4.59B | 36.30 | 8.67% | ― | 11.49% | -2.89% | |
63 Neutral | $4.24B | 27.28 | 9.81% | 0.29% | 9.19% | 23.06% | |
60 Neutral | $7.25B | 148.92 | 2.40% | ― | 11.74% | ― | |
60 Neutral | $6.48B | -17.96 | -4.69% | ― | 6.23% | 17.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $5.39B | -5.94 | -5.26% | 1.11% | 5.43% | -245.18% |
* Healthcare Sector Average
RGEN
Repligen
128.73
-26.65
-17.15%
ATR
AptarGroup
143.71
-0.94
-0.65%
MMSI
Merit Medical Systems
77.18
-25.85
-25.09%
TFX
Teleflex
122.06
-11.58
-8.67%
STVN
Stevanato Group
15.52
-2.54
-14.06%
BLCO
Bausch + Lomb Corporation
18.30
2.44
15.38%
Repligen Corporate Events
Business Operations and StrategyExecutive/Board Changes
Repligen Appoints Martin Madaus as New Board Chair
Positive
Jan 6, 2026
On January 6, 2026, Repligen Corporation announced that its board has elected independent director Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026, succeeding Executive Chair Tony Hunt, who will retire from the board on that date after more than a decade of leadership and will remain an advisor to the company through March 2027. The transition underscores Repligen’s effort to maintain strong governance and continuity in its bioprocessing-focused strategy, with management highlighting Madaus’s 36 years of industry experience—including his tenure leading Millipore’s transformation into a life sciences leader—as a key asset expected to support Repligen’s next phase of growth while reassuring stakeholders about stability in its leadership and long-term direction.
The most recent analyst rating on (RGEN) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Repligen stock, see the RGEN Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.